-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA ACCEPTS CINGULATE’S NEW DRUG APPLICATION FOR CTX-1301 IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) AND SETS A MAY 31, 2026 PDUFA DATE

Reuters·10/14/2025 12:00:05

Please log in to view news